Published in Blood Weekly, September 21st, 2006
According to recent research published in the journal Biotechnology and Bioengineering, "Human embryonic stem cells (hESCs) represent an important resource for novel cell-based regenerative medical therapies.
"hESCs are known to differentiate into mature cells of defined lineages through the formation of embryoid bodies (EBs) which are amenable to suspension culture for several weeks. However, EBs derived from hESCs in standard static cultures are typically nonhomogeneous, leading to inefficient cellular development."
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.